Evaluating a Brightening Serum for Post-Inflammatory Hyperpigmentation
A Single-Center, Open-Label Study to Assess the Efficacy and Tolerability of a Brightening Serum in Skin of Color Patients With Post Inflammatory Hyperpigmentation
This study is designed to evaluate the effectiveness and safety of Vinoperfect, a skin-brightening serum, for treating post-inflammatory hyperpigmentation (PIH), or dark spots that can develop after acne, in participants with Fitzpatrick Skin Types IV-VI (medium to deep skin tones). The study will assess Vinoperfect as part of a comprehensive skincare routine that includes cleansing, treatment, moisturization, and protection from sunlight.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
This is a single-center, open-label trial designed to assess the efficacy and tolerability of a skin brightening serum in individuals with skin of color who are diagnosed with acne-induced Post-Inflammatory Hyperpigmentation on the facial skin. The study will be conducted at a single site, enrolling male and female participants from a range of ethnic/racial backgrounds, all with Fitzpatrick Skin Types IV-VI. Study participation will last for 12 weeks.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Andrew Alexis, MD, MPH
- Phone Number: 6469623376
- Email: dermres@med.cornell.edu
Study Contact Backup
- Name: Angelica Nazarian, MD
- Phone Number: 6469622090
- Email: dermres@med.cornell.edu
Study Locations
-
-
New York
-
New York, New York, United States, 10022
- Recruiting
- Weill Cornell Medicine Dermatology
-
Contact:
- Angelica Nazarian, MD
- Phone Number: 6469622090
- Email: dermres@med.cornell.edu
-
Contact:
- Olumayowa Adebiyi, MD, MHS
- Phone Number: 6469626054
- Email: dermres@med.cornell.edu
-
Principal Investigator:
- Andrew Alexis, MD, MPH
-
Sub-Investigator:
- Angelica Nazarian, MD
-
Sub-Investigator:
- Olumayowa Adebiyi, MD, MHS
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female participants aged ≥18 years.
- Participants with Fitzpatrick Skin Types IV, V, or VI.
- Participants of any ethnicity.
- Presenting with moderate to severe post-inflammatory hyperpigmentation, as determined by a PAHPI score of 8 or higher.
- Presenting with history or presence of mild acne, as indicated by a Global Acne Severity Score of 2 or lower (GEA ≤ 2).
- Capable of understanding and communicating in English, and willing to provide written informed consent to participate in the study.
- Willing to comply with study requirements, including attending all scheduled in-person follow-up visits as outlined in the protocol.
- Willing to undergo facial photography.
- Willing to undergo facial examination for clinical evaluation.
- In good general health, free of any other dermatologic conditions that may interfere with the assessment of the treated area.
- Willing to refrain from using any other facial skincare products during the study period.
- Willing to avoid excessive sun exposure and tanning beds during the study period.
- Willing to refrain from undergoing chemical peels, laser rejuvenation, or hair removal treatments during the study period.
- For females of childbearing potential: willing to use at least one reliable form of contraception, defined as stable use of oral or systemic contraceptives for at least 6 months prior to Day 1 of the study and throughout the study duration.
Exclusion Criteria:
- Participants with Fitzpatrick Skin Types I, II, or III.
- Pregnant or breastfeeding participants.
- Individuals presenting with moderate to very severe acne, as indicated by a Global Acne Severity Score of 3 or higher (GEA > 3).
- Participants with known allergies or sensitivities to any active or inactive ingredients in the study products.
- Participants with dermatologic conditions that may interfere with the evaluation of the treatment area.
- Individuals with regular sun exposure or frequent use of tanning salons.
- Participants currently enrolled in another clinical study.
- Participants who have used the following treatments or procedures within a specific washout periods (to be discussed with the study investigators).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Participants with Acne-Associated Post-Inflammatory Hyperpigmentation using the Vinoperfect Serum
Participants will undergo a standardized twice-daily skincare regimen for 12 weeks. In the morning, participants will cleanse their face, apply the Vinoperfect Brightening Serum, apply moisturizer, and then apply SPF 50+ sunscreen. In the evening, participants will cleanse their face, apply the Vinoperfect Brightening Serum, and apply moisturizer. |
Participants will undergo a standardized twice-daily skincare regimen for 12 weeks. In the morning, participants will cleanse their face, apply the Vinoperfect Brightening Serum, apply moisturizer, and then apply SPF 50+ sunscreen. In the evening, participants will cleanse their face, apply the Vinoperfect Brightening Serum, and apply moisturizer. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline in PIH of the face at Week 12, as assessed by the Post-Acne Hyperpigmentation Index (PAHPI) score
Time Frame: Baseline; 12 weeks
|
Total scores on the PAHPI range from 6 to 22, with higher scores indicating greater severity of post-acne hyperpigmentation |
Baseline; 12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number or participants who tolerated the investigational product as assessed by the investigator
Time Frame: Up to 12 weeks
|
Investigator-assessed tolerability of the investigational product based on the presence and severity of local or systemic adverse reactions potentially attributable to the investigational product. |
Up to 12 weeks
|
|
Patient-reported stigmatization, as measured by the PUSH-D questionnaire at week 12
Time Frame: Baseline; Week 12
|
Change from baseline in Patient-Reported Stigmatization, as measured by the PUSH-D (Patient Use and Satisfaction with Hyperpigmentation Dermocosmetic) questionnaire at Week 12. The PUSH-D is a 17-item patient-reported questionnaire assessing felt and enacted stigma associated with visible skin conditions. Total score range from 0 to 68 with higher scores indicating more felt/perceived stigma. |
Baseline; Week 12
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Andrew Alexis, MD, MPH, Weill Medical College of Cornell University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 26-01029789
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.